CHRS vs. GLUE, ALVR, DBVT, VIGL, BLUE, SRRK, CMPX, HUMA, KOD, and SOPH
Should you be buying Coherus BioSciences stock or one of its competitors? The main competitors of Coherus BioSciences include Monte Rosa Therapeutics (GLUE), AlloVir (ALVR), DBV Technologies (DBVT), Vigil Neuroscience (VIGL), bluebird bio (BLUE), Scholar Rock (SRRK), Compass Therapeutics (CMPX), Humacyte (HUMA), Kodiak Sciences (KOD), and SOPHiA GENETICS (SOPH). These companies are all part of the "biological products, except diagnostic" industry.
Coherus BioSciences vs.
Monte Rosa Therapeutics (NASDAQ:GLUE) and Coherus BioSciences (NASDAQ:CHRS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, community ranking, dividends, media sentiment, institutional ownership, profitability, valuation and earnings.
83.2% of Monte Rosa Therapeutics shares are held by institutional investors. Comparatively, 99.5% of Coherus BioSciences shares are held by institutional investors. 5.3% of Monte Rosa Therapeutics shares are held by insiders. Comparatively, 11.0% of Coherus BioSciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Monte Rosa Therapeutics has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500. Comparatively, Coherus BioSciences has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500.
Monte Rosa Therapeutics presently has a consensus target price of $17.75, indicating a potential upside of 135.10%. Coherus BioSciences has a consensus target price of $16.14, indicating a potential upside of 302.57%. Given Coherus BioSciences' stronger consensus rating and higher probable upside, analysts clearly believe Coherus BioSciences is more favorable than Monte Rosa Therapeutics.
In the previous week, Coherus BioSciences had 6 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 8 mentions for Coherus BioSciences and 2 mentions for Monte Rosa Therapeutics. Monte Rosa Therapeutics' average media sentiment score of 0.15 beat Coherus BioSciences' score of -0.37 indicating that Monte Rosa Therapeutics is being referred to more favorably in the media.
Monte Rosa Therapeutics has higher earnings, but lower revenue than Coherus BioSciences. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Coherus BioSciences, indicating that it is currently the more affordable of the two stocks.
Monte Rosa Therapeutics has a net margin of 0.00% compared to Coherus BioSciences' net margin of -148.01%. Coherus BioSciences' return on equity of 0.00% beat Monte Rosa Therapeutics' return on equity.
Coherus BioSciences received 414 more outperform votes than Monte Rosa Therapeutics when rated by MarketBeat users. Likewise, 64.97% of users gave Coherus BioSciences an outperform vote while only 33.33% of users gave Monte Rosa Therapeutics an outperform vote.
Summary
Coherus BioSciences beats Monte Rosa Therapeutics on 11 of the 17 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CHRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Coherus BioSciences Competitors List
Related Companies and Tools
